Skip to main content
Clinical Trials/NCT04118179
NCT04118179
Active, not recruiting
Not Applicable

Development of a New Strategy to Predict Early Sepsis

University of British Columbia5 sites in 5 countries1,000 target enrollmentAugust 1, 2018
ConditionsSepsis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sepsis
Sponsor
University of British Columbia
Enrollment
1000
Locations
5
Primary Endpoint
Severity of illness
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

This is an observational prospective multicentre study on patients attending the emergency department and suspected to have sepsis. Blood markers characteristic of a Cellular Reprogramming (CR) signature and predicting severe sepsis and organ failure will be measured and validated.

Detailed Description

Sepsis is a life-threatening medical condition caused by an infection and the complex and dysfunctional way by which the human body attempts to deal with it. It can affect people of all ages, causing 18-30 million cases and 5-8 million deaths annually worldwide. However, early diagnosis of sepsis is challenging due to the diversity and overlap of symptoms with other disorders and the lack of an early and accurate diagnostic method. Hancock and colleagues defined a gene expression signature characteristic of biological changes occurring during sepsis, known as cellular reprogramming (CR) and reflecting a type of immune amnesia (inability to respond to bacterial signals). This signature was shown to predict the development of sepsis and organ failure at first clinical presentation in the emergency room, by examining patient blood samples taken during an initial pilot single-center study. This project will validate and refine the CR signature and demonstrate reproducibility, specificity, and sensitivity in a larger multi-center study to enable a new strategy to predict Sepsis.

Registry
clinicaltrials.gov
Start Date
August 1, 2018
End Date
July 31, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Bob Hancock

Canada Research Chair and Professor, Department of Microbiology and Immunology

University of British Columbia

Eligibility Criteria

Inclusion Criteria

  • Male or female
  • Presenting to the Emergency Department
  • Attending physician suspects possible sepsis based on at least 2 sign of Systemic inflammatory response syndrome (SIRS) criteria and suspicion of infection

Exclusion Criteria

  • Patient is terminal (death anticipated in 12 hours)
  • Informed consent unobtainable if the subject survives to hospital discharge.
  • Subjects who are unable to provide blood as a standard of care.
  • Blood sample could not be taken within 24 hours of a physician's first contact with the patient.

Outcomes

Primary Outcomes

Severity of illness

Time Frame: 24 hours

Measured by serial Sequential Organ Failure Assessment (SOFA) score monitoring

Secondary Outcomes

  • Mortality(28 days)
  • ICU length of stay(28 days)
  • Sequential Organ Failure Assessment (SOFA) Score monitoring(72 hours)
  • Quick Sequential Organ Failure Assessment (SOFA) Score greater than 2(6 hours)

Study Sites (5)

Loading locations...

Similar Trials